3rd Annual European Congress on Immunotherapies in Cancer™

3rd Annual European Congress on Immunotherapies in Cancer™


21-22 September, 2018
Hilton Barcelona

589-591 Avenida Diagonal
Barcelona, Spain 08014

 

Overview

The clinical development of immunotherapies is undoubtedly one of the hottest areas in cancer research today. It is now well appreciated that the tumor microenvironment and the host immune system play important roles in cancer biology. With that understanding, modern-day immunotherapeutic approaches have emerged that do not directly target cancer cells, but harness the adaptive and innate powers of the immune system to combat cancer. These innovative strategies have been practice-changing for the management of a number of malignancies and continue to transform the way clinicians think about treating cancer. While the integration of landmark trial data and new strategies is occurring on an ongoing basis, preclinical and clinical data continue to rapidly accumulate on immunotherapy basic science.

The rapid pace with which new and practice-changing information is emerging creates practice and/or educational gaps for busy clinicians who strive to maintain state-of-the-art care for their patients with cancer. Educational initiatives that allow experts to place noteworthy evidence of immunotherapeutic strategies in its proper clinical context will bridge these educational gaps and optimize clinical practices.

The European Congress on Immunotherapies in Cancer™ is a 2-day comprehensive and interactive program focused exclusively on immunotherapies and their practical application to the management of cancer. This intensive, interactive program will provide a comprehensive review of key data sets that are most relevant for the clinician who manages some of the most difficult-to-treat forms of cancer. The program will focus on scientific advances, recent clinical trial results that shape current and evolving uses of these approaches, proactive methods to monitor and mitigate treatment-related adverse events, current and emerging testing methods, and multidisciplinary team approaches to optimize the use of immunotherapeutic strategies to treat cancer.

Benefits of Attending

  • Discover which recent data on immunotherapies you should integrate into your practice
  • Network with top immunotherapy clinicians and scientists
  • Participate in group discussions about current challenges and controversies
  • Learn best practices around the use of immunotherapies for liquid and solid tumors
  • Gain a higher level understanding of established and emerging immunotherapies
Target Audience

This educational activity is intended for medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.). Participants will primarily be those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of cancer.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Explain mechanistic approaches toward targeting the immune system to treat cancer
  • Evaluate the clinical applicability of data from clinical trials of immunotherapy strategies
  • Discuss methods to individualize the use of immunotherapy strategies, including the use of biomarkers
  • Describe how to proactively mitigate and manage adverse events associated with the use of treatment strategies used in the care of patients with cancer
  • Identify unmet clinical needs in cancer treatment and highly anticipated clinical trials evaluating novel immunotherapeutic approaches

Program Chair

Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular and Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California, USA

Program Chair

Caroline Robert, MD PhD
Head of the Dermatology Unit
Department of Medicine
Gustave Roussy and Paris-Sud University
Villejuif Grand - Paris, France
 

European Planning Committee

John Haanen, PhD
Head of the Division of Medical Oncology and
Staff Scientist in the Division of Immunology
The Netherlands Cancer Institute
Professor of Translational Immunotherapy of
Cancer Leiden University Medical Center
Amsterdam, Netherlands

Joan Carles, MD, PhD
Associate Professor of Medicine
UIC Director GU
CNS and Sarcoma Program
Department of Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain

Jose A. Lopez-Martin, MD, PhD
Chairman, GETICA
(Grupo Español de Terapias Inmuno-Biologicas en Cancer / Spanish Group for Cancer Immuno-Biotherapy)
Early Clinical and Translational Research Unit
Sarcoma & Melanoma Programme Medical Oncology Department,
'12 de Octubre' University Hospital
Madrid, Spain







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By